The 13th International Congress on aPL recommended to study IgA anti-β2-GP1 and IgA aCL only in patients with clinical APS signs, negative for IgG/IgM anti-β2-GP1 and IgG/IgM aCL [8]. This evidence concerns the gene CD79A and autoimmune polyendocrinopathy.